The NCRI Haematological Group has seven subgroups that develop research in areas of strategic need.
The Acute Lymphoblastic Leukaemia (ALL) Subgroup, chaired by Dr Clare Rowntree, develops research into Acute lymphoblastic leukaemia, a type of blood cancer that starts from young white blood cells called lymphocytes in the bone marrow.
Members:
Clare Rowntree, Cardiff and Vale University Health Board (CVUHB) (subgroup chair)
Thomas Fox, University College London Hospitals NHS Foundation Trust (UCLH)
Rachael Hough, University College London Hospitals NHS Foundation Trust (UCLH)
Amy Kirkwood, Senior Statistician, Cancer Research UK (CRUK) London – Clinical Trials Unit @ University College London (UCL)
David Marks, University Hospitals Bristol NHS Foundation Trust
Andrew McMillan, Consultant Haematologist, Nottingham University Hospitals NHS Trust
Tobias Menne, Newcastle upon Tyne Hospitals NHS Foundation Trust
Anthony Moorman, Professor of Genetic Epidemiology, Newcastle University
Nicholas Morley, Sheffield Teaching Hospitals NHS Foundation Trust
Gillian Murphy, NCRI Consumer Forum member
Oliver Ottmann, Professor and Head of Haematology, Cardiff University
Bella Patel, University College London (UCL)
John Reeve, NCRI Consumer Forum member
The Acute Myeloid Leukaemia (AML) Subgroup, chaired by Professor Charles Craddock, develops research into acute myeloid leukaemia, a type of blood cancer that starts from white blood cells called granulocytes or monocytes in the bone marrow.
Members:
Charles Craddock, Director of the Blood and Marrow Transplant Unit & Professor of Haemato-oncology, University of Birmingham (subgroup chair)
Sahra Ali, Hull Royal Infirmary
David Bowen, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary
Richard Castle, NCRI Consumer Forum member
Jamie Cavenagh, Queen Mary University of London
Richard Clark, University of Liverpool
Mhairi Copland, Professor of Translational Haematology and Honorary Consultant, University of Glasgow
Dominic Culligan, NHS Grampian – Aberdeen Royal Infirmary
Mike Dennis, Consultant Haematologist, Christie NHS Foundation Trust
Sylvie Freeman, King’s College London (KCL)
Ann Hunter, King’s College London (KCL)
Brian Huntly, University of Cambridge
Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust
Harpreet Kaur, Sheffield Teaching Hospitals NHS Foundation Trust
Asim Khwaja, University College London (UCL)
Steven Knapper, Cardiff University
Panos Kottaridis, University College London Hospitals NHS Foundation Trust (UCLH)
Robert Lown, University Hospital Southampton NHS Foundation Trust – Princess Anne Hospital
Mary McMullin, Queen’s University Belfast
Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust
Francis Mussai, Clinical Senior Lecture Consultant, University of Birmingham
Shamyla Siddique, Haematology Trials Team Leader, University of Birmingham
Paresh Vyas, Consultant Haematology, MRC Weatherall Institute of Molecular Medicine
The Chronic Lymphocytic Leukaemia (CLL) Subgroup, chaired by Dr Anna Schuh, develops research into chronic lymphocytic leukaemia, cancer that develops from lymphoid blood stem cells.
Members:
Anna Schuh, Director for Molecular Diagnostics, University of Oxford (subgroup chair)
David Allsup, Hull Royal Infirmary
Garry Bisshopp, NCRI Consumer Forum member
Adrian Bloor, Christie NHS Foundation Trust
Dena Cohen, University of Leeds
Stephen Devereux, King’s College London (KCL)
Martin Dyer, Professor of Haemato-Oncology, University Hospitals of Leicester NHS Trust
Dima El-Sharkawi, , No affiliation
Chris Fegan, Cardiff and Vale University Health Board (CVUHB)
Francesco Forconi, University of Southampton
Christopher Fox, Consultant Haematologist, Nottingham University Hospitals NHS Trust
Peter Hillmen, Professor of Experimental Haematology, University of Leeds
Parag Jasani, No affiliation
Ben Kennedy, University Hospitals of Leicester NHS Trust
Scott Marshall, South Tyneside and Sunderland NHS Foundation Trust
Nicolas Martinez, Nottingham University Hospitals NHS Trust
Chris Pepper, Cardiff University
Andrew Pettitt, Professor of Haematology Molecular and Clinical Cancer Medicine, University of Liverpool
Christopher Pocock, East Kent Hospitals University NHS Foundation Trust
Guy Pratt, University of Birmingham
Nick York, Trustee, CLL Support Association, CLL Support Association
The Chronic Myeloid Leukaemia (CML) Subgroup, chaired by Dr Dragana Milojkovic, develops research into chronic myeloid leukaemia, a type of cancer that develops from myeloid blood stem cells.
Members:
Dragana Milojkovic, Consultant Haematologist, Imperial College London (subgroup chair)
Jane Apperley, Chair of the Department of Haematology, Imperial College London
Nauman Butt, Royal Liverpool and Broadgreen University Hospitals NHS Trust
Jenny Byrne, University of Nottingham
Richard Clark, University of Liverpool
Mhairi Copland, Professor of Translational Haematology and Honorary Consultant, University of Glasgow
Sandy Craine, King’s College London (KCL)
Joanne Ewing, Heart of England NHS Foundation Trust
Paolo Gallipolli, University of Cambridge
Andrew Goringe, King’s College London (KCL)
Brian Huntly, University of Cambridge
Stephen O’Brien, Newcastle upon Tyne Hospitals NHS Foundation Trust
Wendy Osborne, Consultant Haematologist, Newcastle upon Tyne Hospitals NHS Foundation Trust
Oliver Ottmann, Professor and Head of Haematology, Cardiff University
Seonaid Pye, Consultant Haematologist, University Hospital Southampton NHS Foundation Trust
Anupama Rao, Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust
Kate Rothwell, Consultant in Haematology
Andres Virchis, Consultant Haematologist, University College London Hospitals NHS Foundation Trust (UCLH)
The Myelodysplastic Syndromes (MDS) Subgroup, chaired by Dr Sally Killick, develops research into conditions that can occur when the blood-forming cells in the bone marrow become abnormal.
Members:
Sally Killick, Consultant Haematologist, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (subgroup chair)
Rebecca Bishop, Senior Trial Coordinator, University of Birmingham
Rachel Blundred, King’s College London (KCL)
David Bowen, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary
Catherine Cargo, King’s College London (KCL)
Jamie Cavenagh, Queen Mary University of London
John Chadwick, CRUK Clinical Training Fellow, Cancer Research UK (CRUK) Manchester Centre
Tim Chevassut, King’s College London (KCL)
Dominic Culligan, NHS Grampian – Aberdeen Royal Infirmary
Christopher Dalley, King’s College London (KCL)
Mark Drummond, NHS Greater Glasgow and Clyde
Simone Green, King’s College London (KCL)
Aimie Houlton, King’s College London (KCL)
Wendy Ingram, King’s College London (KCL)
Harpreet Kaur, Sheffield Teaching Hospitals NHS Foundation Trust
Austin Kulasekararaj, King’s College London (KCL)
Judith Marsh, King’s College London (KCL)
Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust
Juliet Mills, King’s College London (KCL)
Ken Mills, Queen’s University Belfast
Ghulam Mufti, King’s College London (KCL)
Jane Parker, Northampton General Hospital
Beth Payne, University College London (UCL)
Manoj Raghavan, King’s College London (KCL)
Kavita Raj, Guy’s and St Thomas’ NHS Foundation Trust
Alexander Sternberg, , King’s College London (KCL)
Paresh Vyas, Consultant Haematology, MRC Weatherall Institute of Molecular Medicine
Sophie Wintrich, King’s College London (KCL)
Dan Wiseman, Cancer Research UK (CRUK) Manchester Institute
The Myeloma Subgroup, chaired by Professor Gordon Cook, develops research into malignant tumours of the bone marrow.
Members:
Gordon Cook, University of Leeds (subgroup chair)
John Ashcroft, Mid Yorkshire Hospitals NHS trust
Holger Auner, , King’s College London (KCL)
Supratik Basu, King’s College London (KCL)
Reuben Benjamin, King’s College London (KCL)
Jenny Bird, University Hospitals Bristol NHS Foundation Trust
Stella Bowcock, Consultant Haematologist, King’s College Hospital NHS Foundation Trust
Sarah Brown, Associate Professor of Statistics in Early Phase Clinical Trials, University of Leeds
Jamie Cavenagh, Queen Mary University of London
Andy Chantry, University of Sheffield
Mike Chapman, University of Cambridge
Mark Cook, Consultant Haematologist, University Hospitals Bristol NHS Foundation Trust
Charles Crawley, Addenbrooke’s Hospital NHS Foundation Trust
Mark Drayson, King’s College London (KCL)
Shirley D’sa University College London Hospitals NHS Foundation Trust (UCLH)
Walter Gregory, Professor of Statistical Methodology in Clinical Trials, University of Leeds
Hannah Hunter, King’s College London (KCL)
Matthew Jenner, University Hospital Southampton NHS Foundation Trust
Martin Kaiser, Institute of Cancer Research (ICR)
Kamaraj Karunanithi, University Hospitals of North Midlands NHS Trust
Bhuvan Kishore, Heart of England NHS Foundation Trust
Eric Low, King’s College London (KCL)
Ceri Marrin, King’s College London (KCL)
Atul Mehta, King’s College London (KCL)
Monica Morris, Myeloma UK
Wendy Notowicz, King’s College London (KCL)
Kim Orchard, Senior Lecturer and Consultant Haematologist, University Hospital Southampton NHS Foundation Trust
Roger Owen, King’s College London (KCL)
Rakesh Popat, University College London (UCL)
Guy Pratt, University of Birmingham
Neil Rabin, Consultant Haematologist, University College London Hospitals NHS Foundation Trust (UCLH)
Karthik Ramasamy, King’s College London (KCL)
Steve Schey, King’s College London (KCL)
Clare Shaw, Assistant speciality Custer Lead, National Institute for Health Research (NIHR)
John Snowden, Sheffield Teaching Hospitals NHS Foundation Trust
Richard Soutar, University of Glasgow
Matthew Streetly, Guy’s and St Thomas’ NHS Foundation Trust
Jane Tighe, King’s College London (KCL)
Cathy Williams, Nottingham University Hospitals NHS Trust
Kwee Yong, University College London (UCL)
The Myeloproliferative Neoplasms (MPN) Subgroup, chaired by Dr Adam Mead, develops research into blood cancers that occur when the body makes too many white or red blood cells or platelets.
Members:
Adam Mead, Professor of Haematology, University of Oxford (subgroup chair)
Sahra Ali, Hull Royal Infirmary
Elizabeth Joanna Baxter, Senior Research Associate, University of Cambridge
Nauman Butt, Royal Liverpool and Broadgreen University Hospitals NHS Trust
Peter Campbell, Head Of Cancer Genetics And Genomics, Wellcome Sanger Institute
Catherine Cargo, King’s College London (KCL)
Eibjilin Conneally, Leeds Teaching Hospitals NHS Trust
Nick Cross, University of Southampton
Mark Drummond, NHS Greater Glasgow and Clyde
Andrew Duncombe, King’s College London (KCL)
Joanne Ewing, Heart of England NHS Foundation Trust
Sonia Fox, University of Birmingham
Sebastian Francis, Sheffield Teaching Hospitals NHS Foundation Trust
Rebecca Frewin, No affiliation
Anna Godfrey, King’s College London (KCL)
Tony Green, University of Cambridge
Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust
Clodagh Keohane, Mercy University Hospital
Steven Knapper, Cardiff University
Jonathan Lambert, University College London Hospitals NHS Foundation Trust (UCLH)
Donal McLornan, King’s College London (KCL)
Mary McMullin, Queen’s University Belfast
Dragana Milojkovic, Consultant Haematologist, Imperial College London
Jyoti Nangalia, University of Cambridge
Alisia O’Sullivan, King’s College London (KCL)
Deepti Radia, Guy’s and St Thomas’ NHS Foundation Trust
Ciro Rinaldi, United Lincolnshire Hospitals NHS Trust
Shekouhi Satareh, Guy’s and St Thomas’ NHS Foundation Trust
Mallika Sekhar, King’s College London (KCL)
Shamyla Siddique, Haematology Trials Team Leader, University of Birmingham
Tim Somervaille, Cancer Research UK (CRUK) Manchester Institute
Frances Wadelin, Nottingham University Hospitals NHS Trust
Jonathan Wallis, Newcastle upon Tyne Hospitals NHS Foundation Trust
Louise Wallis, Royal Brompton & Harefield NHS Foundation Trust
Claire Woodley, Guy’s and St Thomas’ NHS Foundation Trust